Immuron Travelers’ Diarrhea Market Update
12 oct. 2020 06h00 HE
|
Immuron Limited
Key Points Immuron’s IMM-124E IND Program recommencesUniformed Services University to recommence planned Travelers’ Diarrhea clinical studyCOVID-19 - Consultancy Agreement with Infectious Disease...
US DoD Naval Medical Research Center Receives FDA Guidance on the clinical development plans for new oral therapeutic
20 juil. 2020 06h00 HE
|
Immuron Limited
Key Points NMRC received guidance from the FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC Two human phase II clinical trials to be conducted in 2021One trial will...
Immuron Partners with CSIRO to produce a new oral therapeutic for clinical evaluation by the US Department of Defense
19 juin 2020 06h00 HE
|
Immuron Limited
Key Points Immuron executes a Research Agreement with The Henry M. Jackson Foundation for Advancement of Military Medicine Inc.Immuron executes a Research Agreement with CSIRO to develop a new oral...
US DoD Naval Medical Research Center Requests Meeting with FDA for Guidance on two Phase 2 trials to Prevent Acute Infectious Diarrhea
09 juin 2020 06h00 HE
|
Immuron Limited
Key Points NMRC requests Pre-IND meeting with FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC Two human phase II clinical trials to be conducted in 2021One trial...
US Department of Defense Reports Final Results from Travelan® Shigellosis Challenge Study
12 juin 2019 07h00 HE
|
Immuron Limited
Key Highlights: Travelan® shigellosis challenge studies in non-human primates successfully completedTravelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated animals...
US Department of Defense Reports Travelan Protects Against Shigella in Primates
05 sept. 2018 10h00 HE
|
Immuron Limited
Key Highlights: Travelan® pre-clinical shigellosis challenge studies in non-human primates (NHP) successfully completedTravelan® prevented clinical shigellosis (bacillary dysentery) in 75% of...
US Department of Defense Research Collaboration Moves Forward
24 juil. 2018 06h28 HE
|
Immuron Limited
Key Highlights: Three US Defense Health funded research projects on Travelan® successfully completedStudies commissioned by the US Department of Defense to evaluate Travelan®’s ability to...
Immuron’s Travelan® Sales Continue to Soar in Third Quarter of FY2018 in Australian & US Markets
23 avr. 2018 09h30 HE
|
Immuron Limited
Key Highlights: US Travelan® sales continue an upward trend with a 95% increase in the Third Quarter of 2018 compared to the same period last year. YTD US sales (End March 2018) climbed to...
US Defense Reports Broad Travelan® Reactivity to 180 Pathogenic Bacteria Including Camylobacter and Shigella
29 janv. 2018 09h20 HE
|
Immuron Limited
Key Highlights: The research program was performed by the U.S. Department of Defense (DoD) and was conducted by the Department of Enteric Diseases, Armed Forces Research Institute of Medical Sciences...
3Gtms Selected by Crowley Logistics as TMS Provider for Department of Defense Contract
10 janv. 2018 10h00 HE
|
3Gtms
SHELTON, Conn., Jan. 10, 2018 (GLOBE NEWSWIRE) -- 3Gtms, Inc., a leading provider of Tier 1 transportation management software, announced today that it has been selected by Crowley Logistics Inc., a...